Back to News
Market Impact: 0.4
A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled
Source: CNBC
Healthcare & BiotechCompany Fundamentals
Genmab shares have doubled in three months following a string of cancer-drug trial wins. The results are strengthening the company’s push to own more of the medicines it develops.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.65
Ticker Sentiment
GMAB0.80
More News
- Binance co-CEO Richard Teng says hackers used fake job interviews, AI tool to steal $6.3 billion in crypto 108511116
- AMD stock jumps 7% on earnings as data center revenue nearly doubles
- Marvell Technology could plunge on latest multibillion-dollar acquisition
- Disney Plans Thousands of Layoffs Companywide
- AMD rides data center riches to ‘largest and most profitable’ quarter in history
- AMD’s OpenAI, Meta chip deals trigger $1 billion quarterly charge